Subscribe to RSS
DOI: 10.1055/s-0038-1661016
Drugs Effect on Platelet Survival Time: Comparison of Two Pyrimido-Pyrimidine Derivatives in Patients with Aortic or Mitral Replacement
Publication History
Received 12 August 1983
Accepted 10 November 1983
Publication Date:
19 July 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198401/lookinside/thumbnails/10-1055-s-0038-1661016-1.jpg)
Summary
A prospective randomized trial of the effects of 2 antiplatelet aggregating drugs, dipyridamole (375 mg/d), a related substance RA 233 (1500 mg/d) and placebo, concomitantly with oral anticoagulants, was carried out in patients with prior valvular replacement. The study was aimed to determine effect on platelet survival time (PST) of these 2 agents. The trial sample consisted of 40 males and 15 females aged 40–70 years (average 53 years). 32 received Björk-Shiley valve in aortic position; 23 underwent mitral valve replacement: 3 with Cooley-Cutter, 11 with Lillehei- Kaster 500 and 9 with Starr-Edwards 6120 prostheses; 28 patients had aortic stenosis, 21 aortic insufficiency. All the PST measured after 3 months of treatment were within normal ranges and not different between placebo, dipyridamole or RA 233 treated subjects: averages in days were, respectively, 7.49, 7.11 and 6.88. The present study did not support the claim that modem valve prosthesis could lead to a shortened PST.
-
References
- 1 Mustard JF, Rowsell HC, Murphy EA. Platelet economy (Platelet survival and turnover). Br J Haematol 1966; 12: 1-24
- 2 Aas KA, Gardner FH. Survival of blood platelets labelled with chromium 51. J Clin Invest 1958; 37: 1257-1268
- 3 Aster RH, Jandl JH. Platelet sequestration in man. I. Methods. J Clin Invest 1964; 43: 843-855
- 4 Murphy EA, Francis ME. The estimation of blood platelet survival: II. The multiple hit model. Thrombos Diathes Haemorrh 1971; 25: 53-80
- 5 Col De Beys C, Ferrant A, Moriau M. Effects of suloctidil on platelet survival time following cardiac valve replacement. Thromb Haemostas 1981; 46: 550-553
- 6 Julliard J, Maupin B, Loverdo A, Bernard J, Colvez P, Lecompte M. Premiers essais de transfusion à l’homme de leucocytes et plaquettes marquées au radio-phosphore. Presse Med 1952; 60: 518-520
- 7 Lander H, Kinlough RL, Robson HN. Reduced platelet survival in patients with Starr-Edwards prostheses. Br Med J 1965; 1: 688-689
- 8 Steele P, Weily H, Davies H, Pappas G, Genton E. Platelet survival time following aortic valve replacement. Circulation 1975; 51: 358-362
- 9 Steele P, Rainwater J, Vogel R. Platelet suppressant therapy in patients with prosthetic cardiac valves. Circulation 1979; 60: 910-913
- 10 Weily H, Genton E. Altered platelet function in patients with prosthetic mitral valves: effects of sulfinpyrazone therapy. Circulation 1970; 42: 967-972
- 11 Weily H, Steele P, Davies H, Pappas G, Genton E. Platelet survival in patients with substitute heart valves. N Engl J Med 1974; 290: 534-537
- 12 Weily H, Steele P, Genton E. Platelet survival in patients with a beall valve: relation to low incidence of thromboembolism. Am J Cardiol 1972; 30: 229-231
- 13 Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-1305
- 14 Sullivan JM, Harken DE, Corlin R. Pharmacological control of thromboembolic complications of cardiac-valves replacement. N Engl J Med 1971; 284: 1391-1394
- 15 Farah E, Cadhilac M, Boubaker A, Starkman C, Acar J. Thromboembolic risk in prosthetic valve carriers. Prevention trial Scand J Haematol 1981; 38 suppl 97-119
- 16 PACTE (Groupe de Recherche) Prévention des accidents thromboemboliques systémiques chez les porteurs de prothéses valvulaires artificielles: essai coopératif contrôle du dipyridamole. Coeur 1978; 9: 915-969
- 17 Najean Y, Dassin E, Renner C, Wacquet M. Cinétique plaquettaire au cours des maladies artérielles. Nouv Presse Med 1979; 8: 3813-3816
- 18 The Panel of Diagnostic Application of Radioisotopes in Hematology. International Committee for Standardization in Hematology. Recommended methods for radioisotope platelet survival studies Blood 1977; 50: 1137-1144
- 19 Dornhorst AC. The interpretation of red cell survival curves. Blood 1951; 6: 1284-1292
- 20 Dassin E, Balitrand N, Najean Y. An analysis of the effect of random and ageing mechanisms on the survival of platelets. Biomedicine 1976; 25: 23-25
- 21 Tsukada T, Tango T. On the methods calculating mean survival time in 52 Cr-platelet survival study. Am J Haematol 1980; 8: 281-290
- 22 Schbath J, Ville D, Mathy B, Sanchini B, Benveniste E, Dechavanne M, Belleville J, Boissel JP. Comparison of 3 methods evaluating platelet survival time in patients with heart valve replacement. Martinus Nijhoff Editor, Netherlands 1983 (in press)
- 23 Seal H. Multivariate statistical analysis for biologists. Mathuen and Co Ltd; London: 1966
- 24 Manohitharajah SM, Rahman AN, Donnelly RJ, Deverall PB, Watson DA. Platelet survival in patients with homograft and prosthetic heart valves: correlation with incidence of thromboembolism. Thorax 1974; 29: 639-642
- 25 Steele P, Genton E. Thromboembolism survival time before and after valve surgery. Adv Cardiol 1976; 17: 189-198
- 26 Stuart RK, McDonald JW, Ahuja SP, Coles JC. Platelet survival in patients with prosthetic heart valves. Am J Cardiol 1974; 330: 840-844
- 27 Steele P, Weily H, Genton E. Effects of sulfinpyrazone on platelet survival adhesion and aggregation. 46th Annual Meeting of the Control Society for Clinical Research 1973; 21: 863 abstract
- 28 Stipe AA, Fink GB. Prophylactic therapy of angina pectoris with organic nitrate: relationship of drug efficacy and clinical experimental design. J Clin Pharmacol 1973; 13: 244-250
- 29 De Boer AC, Han P, Turpie AG G, Butt R, Gent M, Genton E. Platelet tests and antiplatelet drugs in coronary artery disease. Circulation 1983; 67: 500-504
- 30 Abrahamsen AF. Platelet studies in man. Scand J Haematol 1968; 14 suppl 7-53
- 31 Kutti J, Weinfeld A. Platelet survival in man. Scand J Haematol 1971; 8: 336-346